UBS AM
FOMX

UBS AM’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

UBS AM’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-66,134
Closed -$397K – 2679
2017
Q4 		$397K Sell
66,134
-40,178
-38% -$242K ﹤0.01% 2046
2017
Q3 		$590K Hold
106,312
– – ﹤0.01% 1890
2017
Q2 		$493K Buy
106,312
+1,633
+2% +$7.29K ﹤0.01% 1892
2017
Q1 		$518K Sell
104,679
-18,556
-15% -$179K ﹤0.01% 1854
2016
Q4 		$1.37M Buy
123,235
+1,059
+0.9% +$9.96K ﹤0.01% 1441
2016
Q3 		$1.13M Sell
122,176
-26,201
-18% -$219K ﹤0.01% 1631
2016
Q2 		$942K Sell
148,377
-514
-0.3% -$3.41K ﹤0.01% 1681
2016
Q1 		$971K Buy
148,891
+50,333
+51% +$325K ﹤0.01% 1648
2015
Q4 		$799K Sell
98,558
-244,299
-71% -$1.83M ﹤0.01% 1831
2015
Q3 		$2.51M Buy
342,857
+56,558
+20% +$576K ﹤0.01% 1322
2015
Q2 		$2.93M Buy
+286,299
New +$3.16M ﹤0.01% 1237

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

UBS AM's FOMX Position: Q1 2018 in Review

UBS AM sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2018, closing a stake of 66,134 shares — an estimated $397K sold.

UBS AM first reported a position in FOMX in Q2 2015 and held it in 11 quarters. The position peaked at $2.93M in Q2 2015. 56 funds tracked by Wall St. Rank hold FOMX as of Q1 2018.

  • UBS AM reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2018 after selling out during the quarter.
  • UBS AM sold 66,134 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2018, an estimated $397K.
  • UBS AM first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 11 quarters.
  • UBS AM's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $2.93M in Q2 2015.
  • 56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2018.

Based on UBS AM's 13F filing for Q1 2018, filed 14 May 2018.